US › Healthcare

Marker Therapeutics Inc (MRKR)

US · Healthcare · Biotechnology

$1.18+3.51%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-1.8M

EPS

$-0.09

EPS estimate

$-0.25

EPS came in at -0.09 against a street estimate of -0.25 — a beat of 64.0%.

Key statistics

Market cap

$19.5M

Forward P/E

0.0

P/B

1.59

Book value

$0.73

EPS (TTM)

$-0.38

52-week high

$2.46

52-week low

$0.84

50-day MA

$1.28

200-day MA

$1.44

Beta

1.53

Analyst view

Analysts rate Marker Therapeutics Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $7.87.

Shareholding

Insiders

5.49%

Institutions

23.80%

Largest institutional holders

Fund	Stake
NEA Management Company, LLC	9.75%
Blue Owl Capital Holdings LP	3.32%
Vanguard Capital Management, LLC	2.33%
Aisling Capital Management LP	1.95%
Renaissance Technologies Corp	1.05%
Geode Capital Management, LLC	0.97%
Advisor Group Holdings, Inc.	0.56%
Vanguard Fiduciary Trust Co	0.52%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Marker Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.